A late-breaking oral presentation highlighting the company's phase one clinical data of its investigational in vivo gene editing therapy, CTX310, targeting angiopoietin-related protein 3 (ANGPTL3) for cardiovascular and cardiometabolic disease, will be presented at the American Heart Association (AHA) Scientific Sessions 2025, taking place November 7-10, 2025, in New Orleans, Louisiana.
Additionally, the company will present a poster presentation on CTX340, its in vivo preclinical program targeting angiotensinogen (AGT) for the treatment of refractory hypertension.
Market Data 
Markets 
AI
